Literature DB >> 16177338

Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells.

Sylvie Bertholet1, Alain Debrabant, Farhat Afrin, Elisabeth Caler, Susana Mendez, Khaled S Tabbara, Yasmine Belkaid, David L Sacks.   

Abstract

CD4(+) and CD8(+) T-cell responses have been shown to be critical for the development and maintenance of acquired resistance to infections with the protozoan parasite Leishmania major. Monitoring the development of immunodominant or clonally restricted T-cell subsets in response to infection has been difficult, however, due to the paucity of known epitopes. We have analyzed the potential of L. major transgenic parasites, expressing the model antigen ovalbumin (OVA), to be presented by antigen-presenting cells to OVA-specific OT-II CD4(+) or OT-I CD8(+) T cells. Truncated OVA was expressed in L. major as part of a secreted or nonsecreted chimeric protein with L. donovani 3' nucleotidase (NT-OVA). Dendritic cells (DC) but not macrophages infected with L. major that secreted NT-OVA could prime OT-I T cells to proliferate and release gamma interferon. A diminished T-cell response was observed when DC were infected with parasites expressing nonsecreted NT-OVA or with heat-killed parasites. Inoculation of mice with transgenic parasites elicited the proliferation of adoptively transferred OT-I T cells and their recruitment to the site of infection in the skin. Together, these results demonstrate the possibility of targeting heterologous antigens to specific cellular compartments in L. major and suggest that proteins secreted or released by L. major in infected DC are a major source of peptides for the generation of parasite-specific CD8(+) T cells. The ability of L. major transgenic parasites to activate OT-I CD8(+) T cells in vivo will permit the analysis of parasite-driven T-cell expansion, differentiation, and recruitment at the clonal level.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16177338      PMCID: PMC1230980          DOI: 10.1128/IAI.73.10.6620-6628.2005

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  44 in total

Review 1.  Antigen presentation by macrophages harboring intravesicular pathogens.

Authors:  P Overath; T Aebischer
Journal:  Parasitol Today       Date:  1999-08

2.  Characterization of the local and systemic immune responses in patients with cutaneous leishmaniasis due to Leishmania major.

Authors:  A Gaafar; B Veress; H Permin; A Kharazmi; T G Theander; A M el Hassan
Journal:  Clin Immunol       Date:  1999-06       Impact factor: 3.969

3.  A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity.

Authors:  Y Belkaid; S Mendez; R Lira; N Kadambi; G Milon; D Sacks
Journal:  J Immunol       Date:  2000-07-15       Impact factor: 5.422

4.  Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells.

Authors:  A Rodriguez; A Regnault; M Kleijmeer; P Ricciardi-Castagnoli; S Amigorena
Journal:  Nat Cell Biol       Date:  1999-10       Impact factor: 28.824

5.  Epitope cleavage by Leishmania endopeptidase(s) limits the efficiency of the exogenous pathway of major histocompatibility complex class I-associated antigen presentation.

Authors:  M R Garcia; S Graham; R A Harris; S M Beverley; P M Kaye
Journal:  Eur J Immunol       Date:  1997-04       Impact factor: 5.532

6.  Presentation via the class I pathway by Leishmania amazonensis-infected macrophages of an endogenous leishmanial antigen to CD8+ T cells.

Authors:  P E Kima; N H Ruddle; D McMahon-Pratt
Journal:  J Immunol       Date:  1997-08-15       Impact factor: 5.422

7.  Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate.

Authors:  Lélia Delamarre; Margit Pack; Henry Chang; Ira Mellman; E Sergio Trombetta
Journal:  Science       Date:  2005-03-11       Impact factor: 47.728

8.  Dissection of the functional domains of the Leishmania surface membrane 3'-nucleotidase/nuclease, a unique member of the class I nuclease family.

Authors:  A Debrabant; E Ghedin; D M Dwyer
Journal:  J Biol Chem       Date:  2000-05-26       Impact factor: 5.157

9.  Development of a system to study CD4+-T-cell responses to transgenic ovalbumin-expressing Toxoplasma gondii during toxoplasmosis.

Authors:  Marion Pepper; Florence Dzierszinski; Amy Crawford; Christopher A Hunter; David Roos
Journal:  Infect Immun       Date:  2004-12       Impact factor: 3.441

10.  Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti-Leishmania immunity.

Authors:  E von Stebut; Y Belkaid; T Jakob; D L Sacks; M C Udey
Journal:  J Exp Med       Date:  1998-10-19       Impact factor: 14.307

View more
  32 in total

1.  Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression.

Authors:  Levi H C Makala; Babak Baban; Henrique Lemos; Ahmed R El-Awady; Phillip R Chandler; De-Yan Hou; David H Munn; Andrew L Mellor
Journal:  J Infect Dis       Date:  2011-01-31       Impact factor: 5.226

Review 2.  Transgenesis and neuronal ablation in parasitic nematodes: revolutionary new tools to dissect host-parasite interactions.

Authors:  J B Lok; D Artis
Journal:  Parasite Immunol       Date:  2008-04       Impact factor: 2.280

3.  Vaccination with TAT-antigen fusion protein induces protective, CD8(+) T cell-mediated immunity against Leishmania major.

Authors:  Katharina Kronenberg; Sven Brosch; Florian Butsch; Yayoi Tada; Naotaka Shibagaki; Mark C Udey; Esther von Stebut
Journal:  J Invest Dermatol       Date:  2010-06-24       Impact factor: 8.551

Review 4.  Recent advancements in cytotoxic T lymphocyte generation methods using carbohydrate-coated liposomes.

Authors:  Yuzuru Ikehara; Masahiro Yamanaka; Takashi Yamaguchi
Journal:  J Biomed Biotechnol       Date:  2010-06-17

5.  Leishmaniasis Vaccine: Where are We Today?

Authors:  Lukasz Kedzierski
Journal:  J Glob Infect Dis       Date:  2010-05

6.  Optimized subunit vaccine protects against experimental leishmaniasis.

Authors:  Sylvie Bertholet; Yasuyuki Goto; Lauren Carter; Ajay Bhatia; Randall F Howard; Darrick Carter; Rhea N Coler; Thomas S Vedvick; Steven G Reed
Journal:  Vaccine       Date:  2009-09-26       Impact factor: 3.641

7.  Down-regulation of dendritic cell signaling pathways by Leishmania amazonensis amastigotes.

Authors:  Lijun Xin; Kui Li; Lynn Soong
Journal:  Mol Immunol       Date:  2008-06-05       Impact factor: 4.407

Review 8.  Dendritic cells in Leishmania major infections: mechanisms of parasite uptake, cell activation and evidence for physiological relevance.

Authors:  Kordula Kautz-Neu; Kirsten Schwonberg; Michael R Fischer; Anja I Schermann; Esther von Stebut
Journal:  Med Microbiol Immunol       Date:  2012-09-16       Impact factor: 3.402

9.  Tracking antigen-specific CD4+ T cells throughout the course of chronic Leishmania major infection in resistant mice.

Authors:  Antonio J Pagán; Nathan C Peters; Alain Debrabant; Flavia Ribeiro-Gomes; Marion Pepper; Christopher L Karp; Marc K Jenkins; David L Sacks
Journal:  Eur J Immunol       Date:  2012-12-11       Impact factor: 5.532

Review 10.  Cutaneous leishmaniasis: immune responses in protection and pathogenesis.

Authors:  Phillip Scott; Fernanda O Novais
Journal:  Nat Rev Immunol       Date:  2016-07-18       Impact factor: 53.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.